

TERRA - Study of a patient cohort with locally advanced or metastatic non-small cell lung cancer treated with Tarceva® (Erlotinib) monotherapy and without progression after at least nine months

Head :Roche Medical Data Center

Last update : 08/23/2022 | Version : 1 | ID : 74128

General

Identification

Detailed name Study of a patient cohort with locally advanced or metastatic non-small cell lung cancer treated with Tarceva® (Erlotinib) monotherapy and without progression after at least nine months

Sign or acronym TERRA

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation

ML22973

General Aspects

Medical area Cancer research

Study in connection with Covid-19 No

Pathology (details) Non-Small Cell Lung Cancer (NSCLC)

Health determinants Iatrogenic
Medicine

Keywords ERLOTINIB

Scientific investigator(s) (Contact)

Name of the director Roche Medical Data Center

Address 4 cours de l'Île Seguin - 92650 BOULOGNE-BILLANCOURT

Email data_sharing_france@roche.com

Organization Roche SAS

Collaborations

Participation in projects, networks and consortia No

Funding

Funding status Private

Governance of the database

Sponsor(s) or organisation(s) responsible Roche SAS

Organisation status Private

Presence of scientific or steering committees Yes

Additional contact

Name of the contact <https://www.roche.fr/fr/innovation-recherche-medicale/data-sharing-portail-d-information-partage-des-donnees.html>

Main features

Type of database

Type of database Study databases

Study databases (details) Cohort study

Database recruitment is carried out by an intermediary A selection of health institutions and services

Database recruitment is made on the basis of: Medication(s) taken

Database recruitment is carried out as part of an interventional study No

Database objective

Main objective Primary objective: To describe the progression-free survival of a population of patients with metastatic or locally advanced NSCLC treated with Tarceva® monotherapy whose disease has not progressed for at least nine months.

Secondary objectives:

- To describe patients' characteristics at inclusion in the study and on initiation of treatment with Tarceva® monotherapy (demographic, clinical, and biological characteristics);
- To describe the use of Tarceva®;
- To evaluate the efficacy of treatment with Tarceva®: the best response obtained (complete response, partial response, or stabilisation), overall survival, and prognostic criteria for long-term survival on Tarceva®;
- To describe the long-term safety profile of Tarceva®;
- To describe the correlations between tumour biology and response to Tarceva®;
- To describe patient adherence to Tarceva® monotherapy using the Morisky scale;
- To describe the change in quality of life for patients treated with Tarceva® monotherapy, using the FACT-L questionnaire.

Inclusion criteria

Inclusion criteria:

- Adult patients (age \geq 18 years);
- Treated with Tarceva® monotherapy for a locally advanced or metastatic NSCLC (stage IIIB/IV) and without disease progression for at least nine months;
- Agreed to be monitored for the whole duration of the observation (24 months maximum);
- Who received both oral and written information about the study without objection to their data being subject to automated processing.

Exclusion criteria:

- None.

Population type

Age

Adulthood (19 to 24 years)
 Adulthood (25 to 44 years)
 Adulthood (45 to 64 years)
 Elderly (65 to 79 years)
 Great age (80 years and more)

Population covered

Sick population

Pathology

D02 - Carcinoma in situ of middle ear and respiratory system

Gender

Male
 Woman

Geography area

National

Data collection

Dates

Date of first collection (YYYY or MM/YYYY) 2010

Date of last collection (YYYY or MM/YYYY) 2013

Size of the database

Size of the database (number of individuals) < 500 individuals

Details of the number of individuals 217

Data

Database activity Data collection completed

Type of data collected Clinical data
Biological data

Clinical data (detail) Medical registration

Details of collected clinical data Validation of selection criteria - Information about the study - Demographic and general data - NSCLC history - Biomarkers if available - Performance status (ECOG) - Tarceva® therapy - Combined treatments - Anticancer treatments after Tarceva® permanent discontinuation - Disease progression - Adverse events under Tarceva® therapy, over the retrospective study period - Adverse events over the prospective study period - Reason for early study withdrawal.

Presence of a biobank No

Health parameters studied Health event/morbidity
Health event/mortality
Health care consumption and services

Care consumption (detail) Medicines consumption

Procedures

Data collection method eCRF

Classifications used CDISC

Quality procedure(s) used	GCP/GVP
Participant monitoring	Yes
Monitoring procedures	Monitoring by contact with the referring doctor
Links to administrative sources	No

Promotion and access

Promotion

Access

Dedicated website	https://www.roche.fr/fr/innovation-recherche-medicale/data-sharing-portail-d-information-partage-des-donnees.html
Presence of document that lists variables and coding procedures	Yes
Access to aggregated data	Access on specific project only
Access to individual data	Access on specific project only